The Chemical Constituents of Endophytic Fungus <i>Trichoderma</i> sp. MFF‐1

Li, Guohong; Wang, Xingbiao; Liu, Fangfang; Dang, Li-Zhi; Li, Lei; Yang, Zhongshan; Xiong, Xiang; Zhang, Ke‐Qin

doi:10.1002/cbdv.200900175

Cited by 9 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deacetylisowortmin ( 163 ) was a new mitorubrin derivative from the culture of Trichoderma sp. MFF-1, an endophytic fungus inside the insecticidal plant Pyrethrum cinerariifolium . The fruit bodies of Hypoxylon rubiginosum contained three new azaphilone derivatives named rubiginosins A ( 164 ), B ( 151 ), and C ( 119 ) .…”

Section: Azaphilonesmentioning

confidence: 99%

Azaphilones: Chemistry and Biology

2013

View full text Add to dashboard Cite

Section: Azaphilonesmentioning

confidence: 99%

Azaphilones: Chemistry and Biology

2013

View full text Add to dashboard Cite

“…Wortmannin was also isolated from Fusarium torulosum and Trichoderma sp. MFF‐1 . This fungal metabolite is an inhibitor of phosphatidylinositol 3′ kinases (PI3Ks) and PI3K‐related kinases (PIKKs), such as DNA‐dependent protein kinase .…”

Section: Fungal Metabolites and Their Synthetic Analogues In Cancer Cmentioning

confidence: 99%

Toward a Cancer Drug of Fungal Origin

Kornienko

Evidente²,

Vurro

et al. 2015

Medicinal Research Reviews

View full text Add to dashboard Cite

Although fungi produce highly structurally diverse metabolites, many of which have served as excellent sources of pharmaceuticals, no fungi-derived agent has been approved as a cancer drug so far. This is despite a tremendous amount of research being aimed at the identification of fungal metabolites with promising anticancer activities. This review discusses the results of clinical testing of fungal metabolites and their synthetic derivatives, with the goal to evaluate how far we are from an approved cancer drug of fungal origin. Also, because in vivo studies in animal models are predictive of the efficacy and toxicity of a given compound in a clinical situation, literature describing animal cancer testing of compounds of fungal origin is reviewed as well. Agents showing the potential to advance to clinical trials are also identified. Finally, the technological challenges involved in the exploitation of fungal biodiversity and procurement of sufficient quantities of clinical candidates are discussed and potential solutions that could be pursued by researchers are highlighted.

show abstract

“…respectively. 156 Many of these biological properties have been attributed to the ability of azaphilones to react with amino groups (amino acids, proteins and nucleic acids). [173][174][175][176][177][178][179] In our chemical analysis of Talaromyces The configuration of the C-7 of mitorubrin (4.33) has been previously determined using CD circular dichroism (CD) spectroscopy curves.…”

Section: Antifungal Assay Antifungal Activity Was Measured Against Camentioning

confidence: 99%

Microbial biodiscovery: Exploring venomous animal associated microbes as sources of new chemical diversity

Iniguez¹

View full text Add to dashboard Cite

Microorganisms produce a large number of medically relevant small molecules through unique biosynthetic mechanisms. These small molecules have been widely used to develop drugs to treat a range of infectious diseases, cancers and other pathologies. In their natural environment microorganisms use these small molecules for signalling or defence. As microorganisms have adapted to different environments, they have greatly expanded their chemical profile and thus the investigation of microorganisms from new environments has often led to the discovery of novel chemistry.Microbes often exist in association with higher eukaryotic hosts and are therefore exposed to unique environments and thus produce unique chemistry. The host organism can benefit by utilising microbial metabolites for their own defence against infections, predators, and for chemical signalling. Interestingly, some venomous animals such as puffer fish and the blue ringed octopus utilise toxins produced by associated microbes to defend against predators. However this chemistry remains largely unexplored for the vast majority of venomous animals. In this study, we investigated metabolites from microbes associated with venomous animals including spiders, centipedes, cone snails, scorpions and wasps.We cultivated microbes from 15 venomous animals to produce a library of ~360 strains. The Chapter 1 Reviews the current status of drug discovery and symbiotic microbial strains involved in producing bioactive metabolites Poster.

show abstract

The Chemical Constituents of Endophytic Fungus Trichoderma sp. MFF‐1

Cited by 9 publications

References 20 publications

Azaphilones: Chemistry and Biology

Azaphilones: Chemistry and Biology

Toward a Cancer Drug of Fungal Origin

Microbial biodiscovery: Exploring venomous animal associated microbes as sources of new chemical diversity

Contact Info

Product

Resources

About